Abstract:Donepezil is the second cholinesterase inhibitor to have become commercially available. It is considered a “second-generation” acetylcholinesterase inhibitor (AChEI) because of its safety profile with...Donepezil is the second cholinesterase inhibitor to have become commercially available. It is considered a “second-generation” acetylcholinesterase inhibitor (AChEI) because of its safety profile with clear advantages over the acridine-based cholinesterase inhibitor tacrine, the first AChEI approved for symptomatic treatment of Alzheimer’s disease (AD). Because of considerable toxicity, tacrine is no longer used since the advent of the second generation of AChEIs.Read More
Publication Year: 2004
Publication Date: 2004-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot